Fig. 1 · Structure
Documents & Downloads
Puxitatug samrotecan
ADC
Puxitatug samrotecan is an antibody-drug conjugate (ADC) targeting B7-H4, featuring a Topoisomerase I inhibitor (TOP1i) as its cytotoxic payload. This compound exhibits significant anti-tumor activity, particularly in hormone receptor-positive and HER2-negative breast cancer models. Researchers can leverage Puxitatug samrotecan in studies aimed at evaluating its efficacy in ADC therapy and exploring novel treatment options for specific breast cancer subtypes.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 2760250-80-2 |
| Applications | ADC |
| Synonyms | AZD 8205; P-Sam |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.